Edition:
United States

Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

1.16USD
22 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.16
Open
$1.17
Day's High
$1.18
Day's Low
$1.15
Volume
2,839,238
Avg. Vol
6,071,376
52-wk High
$2.47
52-wk Low
$0.73

Chart for

About

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates... (more)

Overall

Beta: 1.96
Market Cap(Mil.): $341.25
Shares Outstanding(Mil.): 294.18
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Novavax Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Aug 08 2017

BRIEF-Novavax reports Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

Aug 08 2017

BRIEF-Novavax announces positive topline data from phase 2 trial and provides path forward for RSV F vaccine programs

* Novavax announces positive topline data from phase 2 older adult trial and provides path forward for RSV F vaccine programs Source text for Eikon: Further company coverage:

Jul 24 2017

BRIEF-Novavax reports Q1 loss per share $0.16

* Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S

May 08 2017

BRIEF-Novavax reports Q1 loss per share $0.16

* Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

May 08 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.45 +0.50
Merck & Co., Inc. (MRK.N) $65.13 -0.47
Sanofi SA (SASY.PA) €84.12 +0.25
GlaxoSmithKline plc (GSK.L) 1,474.00 +6.00
AstraZeneca plc (AZN.L) 4,912.00 +143.50

Earnings vs. Estimates